3 ways to prevent head and neck cancer
Throat cancer is one of the fastest-growing cancers, and it is often linked to human papillomavirus (HPV). Oropharyngeal cancer, or throat cancer, is a type of head and neck cancer that can be divided into two subgroups: HPV-associated cancers and non-HPV-associated cancers. And depending on the type of subgroup, they are treated differently.
Katharine Price, M.D., a medical oncologist with the Mayo Clinic Comprehensive Cancer Center in Rochester, says there are three ways to reduce your risks and help prevent head and neck cancer.
Tobacco and alcohol use increase the risk of non-HPV tumors, while HPV is responsible for about 70% of head and neck cancers.
'What's important about that is they have different biology and are much more treatable, meaning they respond better to treatments and tend to have a higher cure rate. We're sort of treating those differently than how we treat some of the non-HPV cancers,' Dr. Price says.
Surgery, radiation and chemotherapy are all treatment options, but Dr. Price says it is better to reduce the risks of infection.
'The big three: no smoking tobacco use, minimizing alcohol and then HPV vaccination,' she says.
'We know that smoking and alcohol are big risk factors for head and neck cancer if you do both. This increases your risk even more,' Dr. Price says.
And she encourages eating a healthy diet.
'We really should be striving to have a good whole-food diet, trying to minimize eating processed foods and refined sugars,' Dr. Price says. 3 ways to prevent head and neck cancer
Prev Post
Newcop Opens its First Store in Dubai with Exclusive Kicks
Comments are closed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
07-08-2025
- Web Release
Study finds long-term health benefits from bariatric surgery and liver transplant
How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. 'Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients,' says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. 'The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight,' Dr. Heimbach says.
Zawya
07-08-2025
- Zawya
Study finds long-term health benefits from bariatric surgery and liver transplant
Dubai, United Arab Emirates - Simultaneous bariatric surgery and liver transplant for patients who are severely obese is safe and improves long-term health outcomes, according to a recent Mayo Clinic study. This combined approach offers a needed solution for these patients who are often denied a lifesaving liver transplant due to their weight. The 10-year study, published in the Journal of Hepatology, compared patients who received only a liver transplant with those who underwent both a liver transplant and bariatric surgery. The combined approach resulted in sustained weight loss, reduced risk of type 2 diabetes and lower risk of fatty liver disease recurrence. Importantly, the combined procedure posed no additional risks compared to liver transplant alone. "We've been amazed by the transformation our patients experience," says Julie Heimbach, M.D., director of Mayo Clinic Transplant Center in Minnesota and the study's senior author. "This dual approach prevents long-term obesity complications like diabetes, heart disease and cancer, while also preventing fatty liver disease recurrence." How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. "Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients," says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. "The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight," Dr. Heimbach says. Bringing together experts from different medical specialties is essential when treating these patients, says Ty Diwan, M.D., Mayo Clinic transplant surgeon and the study's co-author. "This study shows that caring for these complex patients extends beyond the transplant itself," Dr. Diwan says. "Multidisciplinary care is required to maximize patient outcomes, and that is what we see in this data. By bringing together experts in very different fields, we've improved patient care and overall health outcomes."
Zawya
31-07-2025
- Zawya
Mayo Clinic discovery could mean better access to more donor hearts and improved transplant outcomes
Dubai, United Arab Emirates — A new discovery by Mayo Clinic researchers could mean more donor hearts are available for heart transplant, giving more people a second chance at life. In findings published in Nature Cardiovascular Research, a team led by Mayo Clinic cardiac surgeon Paul Tang, M.D., Ph.D., identified a biological process that contributes to donor heart injury during cold storage. The researchers found that a drug already used to treat heart conditions can prevent this damage. Heart transplantation is the most effective treatment for end-stage heart failure, yet fewer than half of donor hearts are ultimately used. One major reason is the relatively short window for transplanting a donated heart into a patient, due to concerns over low donor heart function that comes from leaving a heart in cold storage too long. Why donor hearts deteriorate in cold storage Although cold storage slows metabolism and helps preserve tissue, prolonged exposure to cold storage conditions can lead to molecular changes that compromise how well the heart performs after transplant. One complication is called primary graft dysfunction, in which the transplanted heart cannot pump blood effectively after surgery. This may affect up to 20% of recipients to varying degrees. To investigate why this damage occurs, the researchers focused on a protein inside heart cells called the mineralocorticoid receptor, which plays a role in how cells respond to stress. During cold storage, they found that this protein undergoes a process in which the protein clumps together in a way that harms the heart cells, called liquid-liquid phase separation. This process promotes cardiac damage from increased inflammation and cell death, making the heart less likely to function well after transplant. Preventing damage with a common drug To test whether the process could be prevented, the researchers treated donor hearts with a drug called canrenone, which blocks mineralocorticoid receptor activity. In human donor hearts stored beyond the typical timeframe, treatment with the drug nearly tripled their pumping strength compared to hearts stored without it. The hearts also showed better blood flow and fewer signs of cell injury. The findings suggest canrenone may help extend the safe storage period for donor hearts by improving the heart's pumping strength to increase chances of a successful transplant. "As a cardiovascular surgeon, I've personally experienced in the operating room how every additional hour of preservation can impact the likelihood of whether a donor heart can return to normal function after transplantation," Dr. Tang says. "This discovery may give us a new tool to preserve heart function for longer during storage, improve transplant outcomes and enhance patient access to lifesaving transplants." The study's findings also have the potential to improve the preservation of other transplantable organs. Similar protein clustering was observed in donor kidneys, lungs and livers during cold storage. This suggests that the same strategy may help expand transplant options across multiple organ systems.
